Cited by 337Alzheimer's disease research and treatmentsLipid metabolism and biosynthesisCholesterol and Lipid Metabolism

APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia

Open access
Sienski, Grzegorz, Narayan, Priyanka, Bonner, Julia Maeve, Kory, Nora, Boland, Sebastian, Arczewska, Aleksandra A., Ralvenius, William T., Akay, Leyla +10 more·2021·Science Translational Medicine

Abstract

APOE4 -disrupted intracellular lipid homeostasis in human and yeast cells was reversed by promoting phospholipid synthesis through choline supplementation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaz4564

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The effects of APOE on the composition of lipid droplets themselves remain unexplored.

    “the effects of APOE on the composition of LDs themselves remains unexplored”

    From APOE4 reshapes the lipid droplet proteome and modulates microglial inflammatory responses (2025) · cites this paper as Sienski et al., 2021

    The Introduction reports that APOE4 astrocytes accumulated more unsaturated triacylglycerides stored in lipid droplets than APOE3 astrocytes, contrary to the unqualified claim that APOE’s effects on droplet composition remain unexplored. The Results clarify that the lipid composition was measured by whole-cell lipidomics, not by directly analyzing isolated droplets. (LLM, conf=0.76)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • APOE ε4 disrupts lipid homeostasis and immune response and causes mitochondrial dysfunction.

    “APOE ε4 is known to disrupt lipid homeostasis and immune response and to cause mitochondrial dysfunction [31–34]”

    From Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers (2026) · cites this paper as [34]

    The Abstract reports that APOE4 disrupted lipid homeostasis in human iPSC-derived astrocytes and yeast, supporting that part of the claim. The passages retrieved for immune response and mitochondrial dysfunction do not report either effect; the References mention a study of mitochondria-associated membranes, but that does not establish mitochondrial dysfunction in this paper. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Increased lipid droplet accumulation in ApoE4-expressing astrocytes has been thought to result from dysregulation of lipid homeostasis in neuroinflammation.

    “Increased LD accumulation in ApoE4-expressing astrocytes has been thought to result from the dysregulation of lipid homeostasis in neuroinflammation (20)(21)(22).”

    From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [21]

    The Results section reports greater lipid-droplet accumulation and altered lipid composition in APOE4-expressing human iPSC-derived astrocytes than in APOE3 counterparts. It does not establish that this occurs in neuroinflammation; the reported interferon-gamma stimulation involved microglia, not astrocytes. No page numbers are available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Blocking fatty acid desaturation through inhibition of stearoyl-CoA desaturase 1 or supplementing cells with choline reduces lipid droplet accumulation in APOE4 iPSCs.

    “Blocking fatty acid desaturation through inhibition of stearoyl-CoA desaturase 1, an enzyme elevated in Alzheimer's disease patient brains, or supplementing cells with choline reduced LD accumulation in APOE4 iPSCs (Astarita et al., 2011; Sienski et al., 2021).”

    From APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size (2024) · cites this paper as Sienski et al., 2021

    The Results sections on lipid desaturation and choline supplementation report that SCD1 inhibition and CDP-choline treatment each reduced lipid droplet numbers. The experiments used APOE4-expressing human iPSC-derived astrocytes, not undifferentiated APOE4 iPSCs as the claim states. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Studies have shown benefits of dietary choline intake and supplementation on cognitive performance in human individuals and in animal models.

    “This finding aligns with studies showing benefits of dietary choline intake and supplementation on cognitive performance in human individuals and in animal models71–78.”

    From Single-cell multiregion dissection of Alzheimer’s disease (2024) · cites this paper as [78]

    The Discussion (page not provided) reports greater efficacy of choline supplementation in clinical trials involving people with Alzheimer’s disease who carry APOE4; the cited trial’s title identifies cognitive performance as an outcome. The paper’s own Results concern lipid defects in cultured cells, while the animal-related study listed in its References reports improved Alzheimer’s pathology, not cognitive performance. The claim’s animal-cognition component is therefore not supported by our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sienski, G., Narayan, P., Bonner, J. M., Kory, N., Boland, S., Arczewska, A. A., Ralvenius, W. T., Akay, L., Lockshin, E., He, L., Milo, B., Graziosi, A., Baru, V., Lewis, C. A., Kellis, M., Sabatini, D. M., Tsai, L.-H., & Lindquist, S.
Affiliations
  • Whitehead Institute for Biomedical Research (US)
  • National Institutes of Health (US)
  • Harvard University (US)
  • Massachusetts Institute of Technology (US)
  • Duke University (US)
  • Broad Institute (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
  • Sienski, Grzegorz
  • Narayan, Priyanka
  • Bonner, Julia Maeve
  • Tsai, Li-Huei
  • Lindquist, Susan
Venue
Science Translational Medicine
Published
2021-03-03
Volume
13
Issue
583
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3135225782
Cited by
336
References
97
Citations by year
2026: 59 · 2025: 80 · 2024: 72 · 2023: 65 · 2022: 42 · 2021: 18
FWCI
30.90
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
Funders
  • National Institutes of Health
  • Howard Hughes Medical Institute
  • National Institute of Mental Health
  • National Heart, Lung, and Blood Institute
  • National Human Genome Research Institute
  • National Institute of Neurological Disorders and Stroke (ALTF 829-2015, NIH/NIA K99, AG055697-03, R01 CA103866, RF1 AG048029, RF1 AG062377, U01 NS110453, R01 AG062335, R01 AG058002)
  • NIH Office of the Director (AG055697-03)
  • National Cancer Institute, Cairo University
  • National Institute of Development Administration
  • Neurodegeneration Consortium
  • NIH Clinical Center (R01 CA103866)
  • Damon Runyon Cancer Research Foundation
  • European Molecular Biology Organization (ALTF 829-2015)
  • Helen Hay Whitney Foundation
  • Alzheimer’s Association (AARF-19-616816)
  • NIH Blueprint for Neuroscience Research (R01 AG062335, R01 AG058002, RF1 AG048029, RF1 AG062377)
  • Robert A. and Renee E. Belfer Family Foundation
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
APOE ε4, glial cells, induced pluripotent stem cells, phospholipid synthesis, choline supplementation, Alzheimer's disease, lipid metabolism
MeSH terms
Alzheimer Disease, Apolipoproteins E, Homeostasis, Humans, Neuroglia, Apolipoprotein E3, Apolipoprotein E4, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review